A comparison of in vitro methods for determining the membrane receptor expression in cell lines

Nuclear Medicine and Biology

Volumn 39, Issue 7, 2012, Pages 893-896

  Novy, Zbynek ^a   Barta, Pavel ^a   Mandikova, Jana ^a   Laznicek, Milan ^a   Trejtnar, Frantisek ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

EGFR; In vitro; KEX method; Receptor number

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IODINE 131; MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY; NUMBER OF EXPRESSED RECEPTORS PER CELL; PANITUMUMAB; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HCT116; CELL STRAIN HEPG2; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERMETHOD COMPARISON; ISOTOPE LABELING; KINETIC EXTRAPOLATION METHOD; LIGAND BINDING; PROTEIN EXPRESSION; RECEPTOR BINDING; WESTERN BLOTTING;

CELL LINE; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STATISTICS AS TOPIC;

EID: 84866019010     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.02.007     Document Type: Article

References (16)

1. Masters J.R.W. Cell line misidentification: the beginning of the end. Nat Rev Cancer 2010, 10(6):441-448.
2. Hulme E.C., Trevethick M.A. Ligand binding assays at equilibrium: validation and interpretation. Br J Pharmacol 2010, 161:1219-1237.
3. Nestor M., Andersson K., Lundqvist H. Characterization of 111In and 177Lu-labeled antibodies binding to CD44v6 using a novel automated radioimmunoassay. J Mol Recognit 2008, 21(3):179-183.
4. Barta P., Björkelund H., Andresson K. Circumventing the requirement of binding saturation for receptor quantification using interaction kinetic extrapolation. Nucl Med Commun 2011, 32:863-867.
5. Brotherick I., Lennard T.W., Wilkinson S.E., Cook S., Angus B., Shenton B.K. Flow cytometric method for the measurement of epidermal growth factor receptor and comparison with the radio-ligand binding assay. Cytometry 1994, 16(3):262-269.
6. Hanna W. Testing for HER2 status. Oncology 2001, 61(Suppl):22-30.
7. Lurje G., Lenz H.J. EGFR signaling and drug discovery. Oncology 2009, 77:400-410.
8. Delbaldo C., Pierge J.Y., Dieras V., Faivre S., Laurence V., Vedovato J.C. Pharmacokinetic profile of cetuximab (Erbitux™) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur J Cancer 2005, 41:1739-1745.
9. Bernardi R., Onofri A., Pistelli M., Maccaroni E., Scartozzi M., Pierantoni C. Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. Core Evidence 2010, 5:61-76.
10. 131I-labelled human growth hormone of high specific radioactivity. Biochem J 1963, 89:114.
11. Song J.Y., Lee S.W., Hong J.P., Chang S.E., Choe H., Choi J. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells. Cancer Lett 2009, 283:135-142.
12. Björkelund H., Gedda L., Andersson K. Avoiding false negative results in specificity analysis of protein-protein interactions. J Mol Recognit 2011, 24(1):81-89.
13. Björke H., Andersson K. Automated, high-resolution cellular retention and uptake studies in vitro. Appl Radiat Isot 2006, 64(8):901-905.
14. Björke H., Andersson K. Measuring the affinity of a radioligand with its receptor using a rotating cell dish with in situ reference area. Appl Radiat Isot 2006, 64(1):32-37.
15. Gedda L., Björkelund H., Andersson K. Real-time immunohistochemistry analysis of embedded tissue. Appl Radiat Isot 2010, 68(12):2372-2376.
16. Nakajima H., Kiyokawa N., Katagiri Y.U., Taguchi T., Suzuki T., Sekino T. Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance. J Biol Chem 2001, 276(46):42915-42922.